rabeprazole has been researched along with Inflammatory Bowel Diseases in 2 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Inflammatory Bowel Diseases: Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Son, M | 1 |
| Park, IS | 1 |
| Kim, S | 1 |
| Ma, HW | 1 |
| Kim, JH | 1 |
| Kim, TI | 1 |
| Kim, WH | 1 |
| Han, J | 1 |
| Kim, SW | 1 |
| Cheon, JH | 1 |
| Maev, IV | 1 |
| Gadzhieva, MG | 1 |
2 other studies available for rabeprazole and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function.
Topics: Animals; Benzene Derivatives; Colitis; Dysbiosis; Imidazoles; Inflammation; Inflammatory Bowel Disea | 2022 |
[Is anti-helicobacter therapy a rational approach in treatment of erosive and ulcerous lesions of the gastroduodenal mucosa in patients with inflamatory bowel diseases?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti | 2005 |